Cuprina Holdings Announces New Clinical Study on Bullfrog Collagen Peptides for Advanced Wound Care and Cosmeceutical Applications

Reuters

06/30

Cuprina Holdings Announces New Clinical Study on Bullfrog Collagen Peptides for Advanced Wound Care and Cosmeceutical Applications

Cuprina Holdings (Cayman) Ltd. has announced progress on several research studies in collaboration with prominent educational institutes focusing on the development of innovative biomedical and cosmeceutical products. The company is exploring the use of collagen peptides derived from American bullfrog skin for diverse applications, including 3D printable wound care dressings and microneedling patches. These studies are conducted in collaboration with the National University of Singapore and the Singapore Institute of Technology. Cuprina is also investigating the production of superior powdered bullfrog collagen peptides for cosmeceuticals. Results from these studies are anticipated to enhance product offerings in wound care and beauty sectors, with ongoing testing to determine their efficacy. Further updates will be provided as research progresses and results become available.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cuprina Holdings (Cayman) Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-017049), on June 30, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2547096241"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2547096241\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2547096241?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-30 19:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2547096241","market":"nz","top_or_hot":-1,"title":"Cuprina Holdings Announces New Clinical Study on Bullfrog Collagen Peptides for Advanced Wound Care and Cosmeceutical Applications","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cuprina Holdings Announces New Clinical Study on Bullfrog Collagen Peptides for Advanced Wound Care and Cosmeceutical Applications\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cuprina Holdings (Cayman) Ltd. has announced progress on several research studies in collaboration with prominent educational institutes focusing on the development of innovative biomedical and cosmeceutical products. The company is exploring the use of collagen peptides derived from American bullfrog skin for diverse applications, including 3D printable wound care dressings and microneedling patches. These studies are conducted in collaboration with the National University of Singapore and the Singapore Institute of Technology. Cuprina is also investigating the production of superior powdered bullfrog collagen peptides for cosmeceuticals. Results from these studies are anticipated to enhance product offerings in wound care and beauty sectors, with ongoing testing to determine their efficacy. Further updates will be provided as research progresses and results become available.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cuprina Holdings (Cayman) Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-017049), on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cuprina Holdings Announces New Clinical Study on Bullfrog Collagen Peptides for Advanced Wound Care and Cosmeceutical Applications</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCuprina Holdings Announces New Clinical Study on Bullfrog Collagen Peptides for Advanced Wound Care and Cosmeceutical Applications\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-30 19:55</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cuprina Holdings Announces New Clinical Study on Bullfrog Collagen Peptides for Advanced Wound Care and Cosmeceutical Applications\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cuprina Holdings (Cayman) Ltd. has announced progress on several research studies in collaboration with prominent educational institutes focusing on the development of innovative biomedical and cosmeceutical products. The company is exploring the use of collagen peptides derived from American bullfrog skin for diverse applications, including 3D printable wound care dressings and microneedling patches. These studies are conducted in collaboration with the National University of Singapore and the Singapore Institute of Technology. Cuprina is also investigating the production of superior powdered bullfrog collagen peptides for cosmeceuticals. Results from these studies are anticipated to enhance product offerings in wound care and beauty sectors, with ongoing testing to determine their efficacy. Further updates will be provided as research progresses and results become available.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cuprina Holdings (Cayman) Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-017049), on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"醫療保健用品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL5JT1nv:1","article_id":"2547096241","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547096241","pubTimestamp":1751284545,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cuprina Holdings Announces New Clinical Study on Bullfrog Collagen Peptides for Advanced Wound Care and Cosmeceutical Applications. Cuprina Holdings  Ltd. has announced progress on several research studies in collaboration with prominent educational institutes focusing on the development of innovative biomedical and cosmeceutical products. The company is exploring the use of collagen peptides derived from American bullfrog skin for diverse applications, including 3D printable wound care dressings and microneedling patches. These studies are conducted in collaboration with the National University of Singapore and the Singapore Institute of Technology. Cuprina is also investigating the production of superior powdered bullfrog collagen peptides for cosmeceuticals. Results from these studies are anticipated to enhance product offerings in wound care and beauty sectors, with ongoing testing to determine their efficacy. Further updates will be provided as research progresses and results beco","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","CUPR":"Cuprina Holdings (Cayman) Limited"},"translate_title":"Cuprina Holdings宣布牛蛙胶原蛋白肽用于高级伤口护理和药妆应用的新临床研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CUPR":0.9},"content_text":"Cuprina Holdings Announces New Clinical Study on Bullfrog Collagen Peptides for Advanced Wound Care and Cosmeceutical Applications\n    \n\n        Cuprina Holdings (Cayman) Ltd. has announced progress on several research studies in collaboration with prominent educational institutes focusing on the development of innovative biomedical and cosmeceutical products. The company is exploring the use of collagen peptides derived from American bullfrog skin for diverse applications, including 3D printable wound care dressings and microneedling patches. These studies are conducted in collaboration with the National University of Singapore and the Singapore Institute of Technology. Cuprina is also investigating the production of superior powdered bullfrog collagen peptides for cosmeceuticals. Results from these studies are anticipated to enhance product offerings in wound care and beauty sectors, with ongoing testing to determine their efficacy. Further updates will be provided as research progresses and results become available.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cuprina Holdings (Cayman) Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-017049), on June 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}